NAVB - Navidea stock soars ~25% on upcoming US patent linked to cancer drug pipeline

• Navidea Biopharmaceuticals ( NYSE: NAVB ) stock rose ~25% after the company said it received a notice of allowance from the U.S. Patent and Trademark Office covering a key component of the company's cancer immunotherapy pipeline.
• The patent application is titled, 'Compositions And Methods For Altering Macrophage Phenotype (US Application #16/832,620).
• Navidea noted that, broadly, the patent covers the ability of the company's constructs to stimulate the body's immune response against tumors through targeted delivery of payloads (e.g., doxorubicin, paclitaxel, and bisphosphonates) that change the nature of macrophages to make them more proinflammatory.
• The company added that in preclinical studies, these constructs have shown the ability to rally an immune response against tumors and make other therapies work more effectively against those tumors
• "This important patent application covers key intellectual property critical to the continued development of our therapeutics pipeline. Our targeted cancer immunotherapeutics have the potential to address the large unmet medical need in oncology," said Navidea's Chief Medical Officer Michael Rosol.

For further details see: